Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 107

1.

Ketamine for depression: where do we go from here?

Aan Het Rot M, Zarate CA Jr, Charney DS, Mathew SJ.

Biol Psychiatry. 2012 Oct 1;72(7):537-47. doi: 10.1016/j.biopsych.2012.05.003. Epub 2012 Jun 16. Review.

2.

Ketamine administration in depressive disorders: a systematic review and meta-analysis.

Fond G, Loundou A, Rabu C, Macgregor A, Lançon C, Brittner M, Micoulaud-Franchi JA, Richieri R, Courtet P, Abbar M, Roger M, Leboyer M, Boyer L.

Psychopharmacology (Berl). 2014 Sep;231(18):3663-76. doi: 10.1007/s00213-014-3664-5. Epub 2014 Jul 20. Review.

PMID:
25038867
3.

[Antipsychotics in bipolar disorders].

Vacheron-Trystram MN, Braitman A, Cheref S, Auffray L.

Encephale. 2004 Sep-Oct;30(5):417-24. Review. French.

PMID:
15627046
4.

Rapid resolution of suicidal ideation after a single infusion of an N-methyl-D-aspartate antagonist in patients with treatment-resistant major depressive disorder.

DiazGranados N, Ibrahim LA, Brutsche NE, Ameli R, Henter ID, Luckenbaugh DA, Machado-Vieira R, Zarate CA Jr.

J Clin Psychiatry. 2010 Dec;71(12):1605-11. doi: 10.4088/JCP.09m05327blu. Epub 2010 Jul 13.

5.

Replication of ketamine's antidepressant efficacy in bipolar depression: a randomized controlled add-on trial.

Zarate CA Jr, Brutsche NE, Ibrahim L, Franco-Chaves J, Diazgranados N, Cravchik A, Selter J, Marquardt CA, Liberty V, Luckenbaugh DA.

Biol Psychiatry. 2012 Jun 1;71(11):939-46. doi: 10.1016/j.biopsych.2011.12.010. Epub 2012 Jan 31.

6.

A randomized add-on trial of an N-methyl-D-aspartate antagonist in treatment-resistant bipolar depression.

Diazgranados N, Ibrahim L, Brutsche NE, Newberg A, Kronstein P, Khalife S, Kammerer WA, Quezado Z, Luckenbaugh DA, Salvadore G, Machado-Vieira R, Manji HK, Zarate CA Jr.

Arch Gen Psychiatry. 2010 Aug;67(8):793-802. doi: 10.1001/archgenpsychiatry.2010.90.

7.

A review of ketamine in affective disorders: current evidence of clinical efficacy, limitations of use and pre-clinical evidence on proposed mechanisms of action.

Naughton M, Clarke G, O'Leary OF, Cryan JF, Dinan TG.

J Affect Disord. 2014 Mar;156:24-35. doi: 10.1016/j.jad.2013.11.014. Epub 2013 Dec 10. Review.

PMID:
24388038
8.

Ketamine as a new treatment for depression: a review of its efficacy and adverse effects.

Katalinic N, Lai R, Somogyi A, Mitchell PB, Glue P, Loo CK.

Aust N Z J Psychiatry. 2013 Aug;47(8):710-27. doi: 10.1177/0004867413486842. Epub 2013 May 9. Review.

PMID:
23661785
9.

Ketamine as a fast acting antidepressant: current knowledge and open questions.

Salvadore G, Singh JB.

CNS Neurosci Ther. 2013 Jun;19(6):428-36. doi: 10.1111/cns.12103. Epub 2013 Apr 12. Review.

PMID:
23578128
10.

Repetitive transcranial magnetic stimulation for the treatment of major depressive disorder: an evidence-based analysis.

Health Quality Ontario.

Ont Health Technol Assess Ser. 2004;4(7):1-98. Epub 2004 Jun 1.

11.

Rapid antidepressant effect of ketamine anesthesia during electroconvulsive therapy of treatment-resistant depression: comparing ketamine and propofol anesthesia.

Okamoto N, Nakai T, Sakamoto K, Nagafusa Y, Higuchi T, Nishikawa T.

J ECT. 2010 Sep;26(3):223-7. doi: 10.1097/YCT.0b013e3181c3b0aa.

PMID:
19935085
12.

Rapid and longer-term antidepressant effects of repeated ketamine infusions in treatment-resistant major depression.

Murrough JW, Perez AM, Pillemer S, Stern J, Parides MK, aan het Rot M, Collins KA, Mathew SJ, Charney DS, Iosifescu DV.

Biol Psychiatry. 2013 Aug 15;74(4):250-6. doi: 10.1016/j.biopsych.2012.06.022. Epub 2012 Jul 27.

13.

Antidepressants for people with epilepsy and depression.

Maguire MJ, Weston J, Singh J, Marson AG.

Cochrane Database Syst Rev. 2014 Dec 3;12:CD010682. doi: 10.1002/14651858.CD010682.pub2. Review.

PMID:
25464360
14.

Family history of alcohol dependence and antidepressant response to an N-methyl-D-aspartate antagonist in bipolar depression.

Luckenbaugh DA, Ibrahim L, Brutsche N, Franco-Chaves J, Mathews D, Marquardt CA, Cassarly C, Zarate CA Jr.

Bipolar Disord. 2012 Dec;14(8):880-7. doi: 10.1111/bdi.12003. Epub 2012 Sep 14.

15.

Intravenous ketamine for treatment-resistant major depressive disorder.

Covvey JR, Crawford AN, Lowe DK.

Ann Pharmacother. 2012 Jan;46(1):117-23. doi: 10.1345/aph.1Q371. Epub 2011 Dec 20. Review.

PMID:
22190250
16.

Efficacy of intravenous ketamine for treatment of chronic posttraumatic stress disorder: a randomized clinical trial.

Feder A, Parides MK, Murrough JW, Perez AM, Morgan JE, Saxena S, Kirkwood K, Aan Het Rot M, Lapidus KA, Wan LB, Iosifescu D, Charney DS.

JAMA Psychiatry. 2014 Jun;71(6):681-8. doi: 10.1001/jamapsychiatry.2014.62.

PMID:
24740528
17.

[Ketamine's antidepressant effect: literature review on clinical use].

De Maricourt P, Jay T, Goncalvès P, Lôo H, Gaillard R.

Encephale. 2014 Feb;40(1):15-23. doi: 10.1016/j.encep.2013.09.001. Epub 2014 Jan 14. Review. French.

PMID:
24434008
18.

Ketamine for treatment-resistant unipolar depression: current evidence.

Mathew SJ, Shah A, Lapidus K, Clark C, Jarun N, Ostermeyer B, Murrough JW.

CNS Drugs. 2012 Mar 1;26(3):189-204. doi: 10.2165/11599770-000000000-00000. Review.

19.

Rapid antidepressant effect of ketamine in the electroconvulsive therapy setting.

Abdallah CG, Fasula M, Kelmendi B, Sanacora G, Ostroff R.

J ECT. 2012 Sep;28(3):157-61. doi: 10.1097/YCT.0b013e31824f8296.

20.

Daily oral ketamine for the treatment of depression and anxiety in patients receiving hospice care: a 28-day open-label proof-of-concept trial.

Irwin SA, Iglewicz A, Nelesen RA, Lo JY, Carr CH, Romero SD, Lloyd LS.

J Palliat Med. 2013 Aug;16(8):958-65. doi: 10.1089/jpm.2012.0617. Epub 2013 Jun 27.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk